Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
Policlinico Universitario di Catania · Ludwig-Maximilians-Universität München
Abstract
Nucleophosmin (NPM1) exon-12 gene mutations are the hallmark of a large acute myelogenous leukemia (AML) subgroup with normal karyotype, but their prognostic value in this AML subset has not yet been determined. We screened 401 AML patients with normal karyotype treated within the German AML Cooperative Group Protocol 99 (AMLCG99) study for NPM1 mutations. Results were related with partial tandem duplications within the MLL gene (MLL-PTD), Fms-like tyrosine kinase 3-length mutations (FLT3-LM), the tyrosine kinase domain of FLT3 (FLT3-TKD), NRAS, KIT, and CEBPA mutations and with clinical characteristics and outcome. NPM1 mutations were detected in 212 (52.9%) of 401 patients. Fourteen mutations, including 8…
Citation impact
- FWCI
- 20.82
- Percentile
- 100%
- References
- 44
Authors
9- SSSusanne SchnittgerCorresponding
Policlinico Universitario di Catania, Ludwig-Maximilians-Universität München
- CSClaudia Schoch
Policlinico Universitario di Catania, Ludwig-Maximilians-Universität München
- WKWolfgang Kern
Policlinico Universitario di Catania, Ludwig-Maximilians-Universität München
- CMCristina Mecucci
Policlinico Universitario di Catania, Ludwig-Maximilians-Universität München
- CTClaudia Tschulik
Policlinico Universitario di Catania, Ludwig-Maximilians-Universität München
Topics & keywords
- NPM1
- Karyotype
- Nucleophosmin
- CEBPA
- Internal medicine
- Biology
- Leukemia
- Oncology